Atrion Corp. announced unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2011. For the quarter, the company reported revenue of $25,519,000 against $26,630,000 in the same period of last year. Operating income was $7,631,000 against $7,755,000 in the same period of last year. Income before income taxes was $7,942,000 against $8,075,000 in the same period of last year. Net income was $5,388,000 against $5,423,000 in the same period of last year. Diluted earnings per share were $2.65 against $2.67 in the same period of last year. For the year, the company reported revenue of $117,704,000 against $108,569,000 in the same period of last year. Operating income was $38,168,000 against $30,977,000 in the same period of last year. Income before income taxes was $39,475,000 against $31,988,000 in the same period of last year. Net income was $26,038,000 against $20,952,000 in the same period of last year. Diluted earnings per share were $12.82 against $10.32 in the same period of last year. Looking forward to 2012, the company anticipate that despite the muddled economic outlook in international markets, where the company generate 42% of sales, fluid delivery and cardiovascular revenues will continue to show healthy increases. The company expect earnings for the full year 2012 could decline by approximately 10% from 2011 levels. The bulk of this decline will be felt in the first two quarters, which will likely show declines of some 20% before tapering off. The company expect to return to double-digit growth pattern in 2013.